Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
January 6, 2016 9:26 AM ESTRoth Capital reiterated a Buy rating and $15.00 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) following the company's reported three-month data from its double-blind, placebo-controlled Phase 2 trial in liver cirrhosis patients. The data indicated that there is a significant functional benefit for severe cirrhotic patients treated with emricasan.
Analyst Elemer Piros commented,... More
Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%
January 5, 2016 4:38 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ET
January 5, 2016 4:11 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET
... More